Familial Alzheimer disease: Decreases in CSF Aβ42 levels precede cognitive decline

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Neurology

• Publication date

  2005-07-26

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/01.wnl.0000171397.32851.bcPMID 16043812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The solved and unsolved mysteries of the genetics of early-onset Alzheimer’s disease

  2007cited by this paper
• CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

  2003cited by this paper
• Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds

  2003cited by this paper
• Screening for PS1 mutations in a referral-based series of AD cases

  2001cited by this paper
• Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

  1995cited by this paper
• Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

  1995cited by this paper
• Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

  1995cited by this paper
• Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Hannah's Heirs: The Quest for the Genetic Origins of Alzheimer's Disease

  1994cited by this paper
• Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

  1993cited by this paper

• Modern biomarkers as key tools in the early diagnosis and monitoring of Alzheimer's disease progression

  2025cites this paper
• Early molecular events of autosomal‐dominant Alzheimer's disease in marmosets with PSEN1 mutations

  2024cites this paper
• Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease.

  2024cites this paper
• Detection and treatment of Alzheimer’s disease in its preclinical stage

  2023cites this paper
• Alzheimer's disease: A role of biomarkers in early diagnosis and evidences from African ethnomedicinal knowledge

  2023cites this paper
• Inflammation-Related microRNAs-146a and -155 Are Upregulated in Mild Cognitive Impairment Subjects Among Older Age Population in Montenegro

  2022cites this paper
• Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington’s disease

  2021cites this paper
• When Does Alzheimer's Disease Really Start? The Role of Biomarkers.

  2021cites this paper
• Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease

  2020cites this paper
• Alzheimer’s disease: from basic science to precision medicine approach

  2020cites this paper
• Salivary biomarkers in Alzheimer's disease

  2020cites this paper
• Current and Developing Methods for Diagnosing Alzheimer's Disease

  2019cites this paper
• When Does Alzheimer′s Disease Really Start? The Role of Biomarkers

  2019cites this paper
• Precision Aging: Applying Precision Medicine to the Field of Cognitive Aging

  2019cites this paper
• Biomarkers for Alzheimer's disease: current status and prospects for the future

  2018cites this paper
• Analyse de la morphologie des sillons corticaux et de l'activation microgliale dans la maladie d'Alzheimer : étude couplée en IRM, TEP-PiB et TEP-DPA

  2018cites this paper
• Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

  2018cites this paper
• Imaging of Neurotransmitter Systems in Dementia

  2016cites this paper
• The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers

  2016cites this paper
• Advances in development of fluorescent probes for detecting amyloid-β aggregates

  2016cites this paper
• Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia

  2015cites this paper
• Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD

  2015cites this paper
• Mapping the Relationship of Contributing Factors for Preclinical Alzheimer’s Disease

  2015cites this paper
• Biomarkers in Sporadic and Familial Alzheimer’s Disease

  2015cites this paper
• Application of the Bead-Based Technique in Neurodegeneration: A Literature Review

  2015cites this paper
• Improving the sensitivity and specificity of LC/MS to enable bioanalysis of therapeutic and endogenous proteins and peptides

  2015cites this paper
• Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease.

  2015cites this paper
• Biomarkers of Alzheimer's Disease

  2015cites this paper
• Alzheimer’s Disease and Other Neurodegenerative Disorders

  2015cites this paper
• Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

  2014cites this paper
• Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats

  2014cites this paper
• CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design

  2014cites this paper
• Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

  2014cites this paper
• Alzheimer Disease Cerebrospinal Fluid Biomarkers Predict Cognitive Decline In Healthy Elderly Over 2 Years

  2014cites this paper
• Gray and White Matter Changes in Subjective Cognitive Impairment, Amnestic Mild Cognitive Impairment and Alzheimer's Disease: A Voxel-Based Analysis Study

  2014cites this paper
• Review - Part of the Special Issue: Alzheimer's Disease - Amyloid, Tau and Beyond Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

  2014cites this paper
• "I don't recognize myself", personality characteristics in subjective cognitive impairment and mild cognitive impairment

  2013cites this paper
• Fluid biomarkers in Alzheimer’s disease – current concepts

  2013cites this paper
• Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid

  2013cites this paper
• Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers

  2013cites this paper
• Relative Ratio and Level of Amyloid-β 42 Surrogate in Cerebrospinal Fluid of Familial Alzheimer Disease Patients with Presenilin 1 Mutations

  2013cites this paper
• Alzheimer’s Disease: A Clinical Perspective

  2013cites this paper
• Fluid biomarkers in Alzheimer's disease - current

  2013cites this paper
• The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

  2013cites this paper
• Potter Presenilin Mutation Carriers 42 Production , Exchange , and Loss in β Increased in Vivo Amyloid

  2013cites this paper
• SPECIFIC AMYLOID-BETA OLIGOMERS IN HUMAN CEREBROSPINAL FLUID

  2012cites this paper
• Diagnostic tools: Fluid biomarkers for Alzheimer's disease

  2012cites this paper
• Genetics of dementia: Update and guidelines for the clinician

  2012cites this paper
• Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals

  2012cites this paper
• Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer’s Disease

  2012cites this paper
• Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease.

  2012cites this paper
• Early-Onset Familial Alzheimer's Disease (EOFAD)

  2012cites this paper
• Fluid biomarkers in Alzheimer disease.

  2012cites this paper
• Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD

  2012cites this paper
• The neuropsychological profile of Alzheimer disease.

  2012cites this paper
• Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry.

  2011cites this paper
• Utility of imaging for nutritional intervention studies in Alzheimer's disease.

  2011cites this paper
• Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients

  2011cites this paper
• Mind the Gap: A Psychometric Approach to the Reduction Problem

  2011cites this paper
• The Usefulness of Biological and Neuroimaging Markers for the Diagnosis of Early-Onset Alzheimer's Disease

  2011cites this paper
• Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cites this paper
• Biomarkers Predicting Alzheimer's Disease in Cognitively Normal Aging

  2011cites this paper
• [Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice].

  2011cites this paper
• Utilisation des biomarqueurs du LCR dans le diagnostic de la maladie d’Alzheimer en pratique clinique

  2011cites this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cites this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup

  2011cites this paper
• Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

  2011cites this paper
• Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease Families with PSEN1 Mutations

  2011cites this paper
• The 7th Leonard Berg Symposium, Part 2

  2010cites this paper
• Diagnóstico precoz de la enfermedad de Alzheimer: fase prodrómica y preclínica

  2010cites this paper
• Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4

  2010cites this paper
• A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer’s disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF

  2010cites this paper
• Pharmacogenetics in neuropsychopharmacology: from clinical associations to intermediate phenotypes of drug response

  2010cites this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cites this paper
• Could Clinical Profile Influence CSF Biomarkers in Early-onset Alzheimer Disease?

  2010cites this paper
• [Early diagnosis of Alzheimer's disease: the prodromal and preclinical phase].

  2010cites this paper
• Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease.

  2009cites this paper
• Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challenges

  2009cites this paper
• Oligomerization Partially Explains the Lowering of Aβ42 in Alzheimer’s Disease Cerebrospinal Fluid

  2009influential citation
• Korrelation klinischer Parameter mit der Anreicherung eines in-vivo Indikators für Amyloid bei Patienten mit Demenz bei Alzheimer-Krankheit

  2009cites this paper
• CSF Studies Facilitate DNA Diagnosis in Familial Alzheimer's Disease Due to a Presenilin-1 Mutation

  2009cites this paper
• Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests

  2009cites this paper
• Long-Term Statin Therapy and CSF Cholesterol Levels: Implications for Alzheimer’s Disease

  2009cites this paper
• Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.

  2009cites this paper
• Biochemical markers in persons with preclinical familial Alzheimer disease

  2008cites this paper
• Children of Persons With Alzheimer Disease: What Does the Future Hold?

  2008cites this paper
• Prominent Neuroleptic Sensitivity in a Case of Early-onset Alzheimer Disease due to Presenilin-1 G206A Mutation

  2008cites this paper
• Dementia of the Alzheimer type.

  2008cites this paper
• Genetics of Alzheimer's Disease. A Rapidly Evolving Field

  2007cites this paper
• Biomarkers for Alzheimer’s disease

  2007cites this paper
• CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment

  2007cites this paper
• AmyloidDepositionBeginsintheStriatumofPresenilin-1 MutationCarriersfromTwoUnrelatedPedigrees

  2007cites this paper
• Les marqueurs biochimiques du LCR : un outil diagnostique de la maladie d’Alzheimer

  2007cites this paper
• Disease-modifying therapies for Alzheimer disease

  2007cites this paper
• CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

  2007cites this paper
• Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease

  2007cites this paper
• Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees

  2007cites this paper
• Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.

  2006cites this paper
• The search for antecedent biomarkers of Alzheimer's disease

  2006cites this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cites this paper